Circulating tumor cell quantification during abiraterone plus prednisone therapy may estimate survival in metastatic castration-resistant prostate cancer patients
International Urology and Nephrology · 2023
DOI: 10.1007/s11255-023-03481-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Urology and Nephrology, 2023. Verfasst von Tengfei Gu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Lishui Municiple Central Hospital, The Fifth Affiliated Hospital of Wenzhou Medical University, No. 289 Kuocang Road, 323000, …. Hauptthemen laut MEDLINE: Neoplastic Cells, Circulating, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE: Circulating tumor cells (CTCs) predict survival in response to different interventions in metastatic castration-resistant prostate cancer (mCRPC) patients. This study aimed to explore the dynamic change in CTCs during abiraterone plus prednisone therapy and its optimal threshold for prognostication in mCRPC patients. METHODS: CTCs in blood samples from mCRPC patients (N = 98) at baseline and in the 2nd month after abiraterone plus prednisone treatment initiation (M2) were enumerated by using the CellSearch System. RESULTS: CTCs were detected in 64.8% of mCRPC patients at baseline with a median value (interquartile range) of 2.0 (0.0-4.0). Elevated CTC count was related to visceral metastasis (P = 0.003), high alkaline phosphatase (P = 0.043), and high lactate dehydrogenase (P = 0.007). Baseline CTC ≥ 1 (vs. < 1) was only associated with shortened radiographic progression-free survival (rPFS) (P = 0.043); additionally, baseline CTC ≥ 5 (vs. < 5) was linked with unfavorable rPFS (P = 0.037) and overall survival (OS) (P = 0.021). Following the therapy, CTCs were reduced at M2 (P < 0.001). Notably, CTC ≥ 1 (vs. < 1) (P = 0.002) and CTC ≥ 5 (vs. < 5) (P < 0.001) at M2 were related to shortened rPFS according to the Kaplan‒Meier curves, and they could independently estimate deteriorative rPFS in the multivariate Cox regression (P = 0.043 and P = 0.027, respectively). Similarly, CTC ≥ 1 (vs. < 1) (P = 0.022) and CTC ≥ 5 (vs. < 5) (P = 0.002) at M2 were related to shortened OS, whereas only CTC ≥ 5 (vs. < 5) could independently predict unfavorable OS (P = 0.017). CONCLUSION: CTC count ≥ 5 at M2 exhibits excellent prognostic value for abiraterone plus prednisone therapy in mCRPC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Lishui Municiple Central Hospital, The Fifth Affiliated Hospital of Wenzhou Medical University, No. 289 Kuocang Road, 323000, Lishui, China.
- Department of Urology, Lishui Municiple Central Hospital, The Fifth Affiliated Hospital of Wenzhou Medical University, No. 289 Kuocang Road, 323000, Lishui, China. fen24840723@163.com.
Zitieren
APA
Gu, T., Li, J., Chen, T., Zhu, Q., & Ding, J. (2023). Circulating tumor cell quantification during abiraterone plus prednisone therapy may estimate survival in metastatic castration-resistant prostate cancer patients. International Urology and Nephrology. https://doi.org/10.1007/s11255-023-03481-9
Vancouver
Gu T, Li J, Chen T, Zhu Q, Ding J. Circulating tumor cell quantification during abiraterone plus prednisone therapy may estimate survival in metastatic castration-resistant prostate cancer patients. International Urology and Nephrology. 2023. doi:10.1007/s11255-023-03481-9
BibTeX
@article{Gu2023,
author = {Gu, Tengfei and Li, Jie and Chen, Ting and Zhu, Qingfeng and Ding, Jiafeng},
title = {Circulating tumor cell quantification during abiraterone plus prednisone therapy may estimate survival in metastatic castration-resistant prostate cancer patients},
journal = {International Urology and Nephrology},
year = {2023},
doi = {10.1007/s11255-023-03481-9}
}
EUVIMED